Category - Developments

Developments

Ocuphire doses first participants in Phase 3 presbyopia study

Ocuphire Pharma (NASDAQ:OCUP) has initiated its VEGA-3 Phase 3 trial, evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia, with its first dose. Topline results are expected in the first half of 2025...

September 6, 2024

Developments

NIH awards TransCode with $2 million grant for lead therapeutic

TransCode Therapeutics (NASDAQ:RNAZ) announced that the National Institutes of Health (NIH) has awarded the company a $2 million Direct to Phase II Small Business Innovation Research grant to support the clinical...

September 5, 2024

Developments

Aurinia reports first participant dosed milestone for potential therapy in autoimmune diseases

Aurinia Pharmaceuticals (NASDAQ:AUPH) has announced that the first participant has been dosed in its Phase 1a study of AUR200, a differentiated, best-in-class potential therapy for autoimmune diseases targeting B-cell...

September 5, 2024

Developments

Valneva and Pfizer announce positive Phase 2 data for Lyme disease booster candidate

Valneva SE (NASDAQ:VALN) and Pfizer (NYSE:PFE) have announced positive Phase II immunogenicity and safety data from a second booster dose of the VLA15 Lyme disease vaccine candidate, administered one year after the...

September 3, 2024

Developments

Praxis reports positive topline results from study of relutrigine in developmental epilepsies

Praxis Precision Medicines (NASDAQ:PRAX) has announced positive topline results from its EMBOLD Phase II proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy...

September 3, 2024

Developments

Nuvectis receives FDA orphan drug designation for NXP800 targeting cancer

The FDA granted orphan drug designation (ODD) to Nuvectis Pharma’s (NASDAQ:NVCT) oral GCN2 activator, NXP800, for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. The ODD could...

August 30, 2024

Developments

Ventyx announces CFO departure and launches search for successor

Ventyx Biosciences (NASDAQ:VTYX) announced the departure of Martin Auster, M.D., as CFO, effective August 30, 2024, and has initiated a search for his successor. The company’s SVP of finance, Ron Gonzales, CPA, MBA, has...

August 30, 2024

Developments

Medigene secures patents advancing TCR-guided therapies

Medigene AG (FSE:MDG1) has announced that patents have been granted for its proprietary JOVI and iM-TCR technologies, enhancing the company’s End-to-End (E2E) platform of TCR-guided therapies for the treatment of cancer...

August 29, 2024

Developments

Gain reports positive topline results from Phase 1 trial of therapy for Parkinson’s

Gain Therapeutics (NASDAQ:GANX) has announced positive results from its Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson’s...

August 29, 2024

Developments

LIXTE and NKI dose first patient with LB100 in colorectal cancer study supported by Roche

LIXTE Biotechnology (NASDAQ:LIXT) has announced that, in collaboration with the Netherlands Cancer Institute (NKI), the first patient has been dosed in a new clinical trial of LUXTE’s lead compound, LB-100, for the...

August 26, 2024

Category - Developments

Ocuphire doses first participants in Phase 3 presbyopia study

NIH awards TransCode with $2 million grant for lead therapeutic

Aurinia reports first participant dosed milestone for potential therapy in autoimmune diseases

Valneva and Pfizer announce positive Phase 2 data for Lyme disease booster candidate

Praxis reports positive topline results from study of relutrigine in developmental epilepsies

Nuvectis receives FDA orphan drug designation for NXP800 targeting cancer

Ventyx announces CFO departure and launches search for successor

Medigene secures patents advancing TCR-guided therapies

Gain reports positive topline results from Phase 1 trial of therapy for Parkinson’s

LIXTE and NKI dose first patient with LB100 in colorectal cancer study supported by Roche

General

More